Australia markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9400-0.0100 (-0.51%)
At close: 04:00PM EST
1.9600 +0.02 (+1.03%)
After hours: 07:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.9500
Open1.9500
Bid1.9400 x 1000
Ask1.9700 x 2200
Day's range1.8700 - 1.9889
52-week range1.8300 - 10.8700
Volume352,366
Avg. volume4,016,606
Market cap21.27M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-6.1070
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Context Therapeutics® Strengthens Research & Development Team

    Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&DPHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current

  • GlobeNewswire

    Context Therapeutics® to Participate in Two January 2022 Investor Conferences

    PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022. Details of the events are as follows: Biotech Showcase™ 2022: The company’s presentation will be available for on-demand viewing dur

  • GlobeNewswire

    Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

    Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that data from the window-of-opportunity clinical trial of onapristone extended rel